SCHEMBL4091233

SCHEMBL4091233

COc1ccc(Oc2ccc(C(=O)CCC(=O)O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.73
ALDH1A1 P00352 1/20 0.67
CYP1A2 P05177 1/20 0.67
HPGD P15428 1/20 0.67
CYP2C19 P33261 1/20 0.67
HSD17B10 Q99714 1/20 0.67
MMP1 P03956 2/20 0.61
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
MAPT P10636 1/20 0.60
HTT P42858 1/20 0.58
KMT2A Q03164 1/20 0.58
HDAC1 Q13547 3/20 0.56
HDAC8 Q9BY41 3/20 0.56
GSK3B P49841 1/20 0.56
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503582 0.95 PDE4B (0.80) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL10885925 0.91 NR4A2 (0.63) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL7864057 0.90 PDE4B (0.73) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL16552644 0.87 MMP1 (0.76) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL4437033 0.86 MMP1 (0.71) PDE4BALDH1A1CYP1A2CYP2C19MMP1
SCHEMBL2413943 0.84 PDE4B (0.93) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL99448 0.84 PDE4B (1.00) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL4483889 0.84 NPC1 (0.77) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL6931569 0.83 RAB9A (0.65) PDE4BALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL8347297 0.83 PDE4B (0.63) PDE4BALDH1A1CYP1A2HPGDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186900-A1 COMPOUND STERIX LIMITED (GB) 2009-07-23 US disclosed
EP-2013176-A2 DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER Sterix Limited (GB) 2009-01-14 EP disclosed
WO-2007096647-A2 DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER STERIX LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186900-A1 COMPOUND HSD17B2, HSD17B11, CYP17A1 PDE4B 1296/4885ALDH1A1 56/4885CYP1A2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.